Abstract
The aim of this study was to develop a model for early prediction of adverse events and treatment effectiveness in patients with hyperkalemia. We collected clinical data from patients with hyperkalemia in the First Hospital of Zhejiang University School of Medicine between 2015 and 2021. The least absolute shrinkage and selection operator (LASSO) and multivariate logistic regression were used to analyze the predictors on the full dataset. We randomly divided the data into a training group and a validation group, and used LASSO to filter variables in the training set. Six machine learning methods were used to develop the models. The best model was selected based on the area under the curve (AUC). Shapley additive exPlanations (SHAP) values were used to explain the best model. A total of 1074 patients with hyperkalemia were finally enrolled. Diastolic blood pressure (DBP), breathing, oxygen saturation (SPO2), Glasgow coma score (GCS), liver disease, oliguria, blood sodium, international standardized ratio (ISR), and initial blood potassium were the predictors of the occurrence of adverse events; peripheral edema, estimated glomerular filtration rate (eGFR), blood sodium, actual base residual, and initial blood potassium were the predictors of therapeutic effect. Extreme gradient boosting (XGBoost) model achieved the best performance (adverse events: AUC = 0.87; therapeutic effect: AUC = 0.75). A model based on clinical characteristics was developed and validated with good performance.
Similar content being viewed by others
Introduction
Hyperkalemia, defined as serum potassium (K +) > 5.5 mmol/L, is a common electrolyte disorder that can disrupt cell membrane potential and action potential transmission1 resulting in potentially life-threatening arrhythmias, and finally is associated with a variety of poor prognoses2. The rise in extracellular potassium ions decreases the resting membrane potential, causing nerve, heart, and muscle tissue to depolarize more readily3. According to serum potassium levels, hyperkalemia can be classified into three grades: mild (5.5–6.5 mmol/L), moderate (6.5–7.5 mmol/L), and severe (> 7.5 mmol/L)4. However, the severity of a patient's clinical presentation not only depends on the serum potassium level but also on the speed of onset, the presence of concomitant electrolyte abnormalities, drug therapy, and other co-morbidities5.
Mild hyperkalemia can present with symptoms such as weakness and chest tightness. Severe hyperkalemia is a medical emergency that can trigger fatal arrhythmias such as ventricular fibrillation, cardiac arrest, sudden cardiac death, and other adverse events6,7, ultimately leading to significant mortality8. According to some studies, potassium itself can cause death, and potassium abnormalities can help identify patients who are sicker, at higher risk of death, or who have heart disease and are physiologically or genetically “unable” to maintain potassium homeostasis9. Because of the potentially fatal symptoms that can occur with hyperkalemia, patients often require prompt and aggressive care in the emergency department6. In patients admitted to the emergency department, hyperkalemia has been described as an independent predictive feature of death10. Physicians need to continuously monitor cardiac function using electrocardiograph in patients with moderate to severe hyperkalemia7 and to perform the laboratory assessment of serum potassium levels11. Risk factors for hyperkalemia include chronic kidney disease12, acute kidney injury (AKI), diabetes, adrenal disease, myocardial dysfunction13, and certain medications4,14. Hyperkalemia requires dose reduction or even discontinuation of treatment with RAASi14,15 at the expense of long-term cardiac and renal benefits, which is one of the major barriers to controlling disease progression. The estimated risk ratios for increased mortality in hyperkalemia patients compared to non- hyperkalemia patients were reported to be 1.116 to 17.717. It has been shown that serum potassium levels are associated with a U-shaped risk of death, and that low potassium levels also increase the risk of death, but the higher the level of potassium, the higher the risk of death18.
A study based on a large U.S. Medicare and commercial claims database containing 1.7 million medical records between 2007 and 2012 showed that the prevalence of hyperkalemia was 34.6% among patients with chronic kidney disease and 30% among patients with heart failure. Hyperkalemia has been a hot topic of clinical research and is being actively explored both in terms of diagnosis and treatment. Hyperkalemia occurs with adverse events associated with higher plasma [K+] values19,20. There are no studies on the short-term prognosis and treatment outcomes of patients admitted to hospitals with hyperkalemia. Because of the significant increases in hospitalization rate and subsequent in-hospital mortality in hyperkalemia, reliable predictors of adverse clinical outcomes and treatment outcomes have not been established, and it is important to understand the factors associated with treatment efficacy and adverse events in a timely manner8. Therefore, we designed this study using a machine learning (ML) algorithm to analyze the clinical data of patients admitted with hyperkalemia in order to develop a model to predict the adverse events and treatment efficacy in patients admitted with hyperkalemia and to screen patients for priority attention.
Methods
Data source
Data for this study were obtained from clinical data of patients admitted with hyperkalemia to the emergency department of the First Hospital of Zhejiang University School of Medicine (Hangzhou, China) from January 2015 to December 2021. We collected the detailed basic information, vital sign measurements, diagnostic information, laboratory information, and treatment information. The study was approved by the Clinical Research Ethics Committee of the First Affiliated Hospital, Zhejiang University School of Medicine. Because this study was a retrospective design, written informed consent was waived with the approval of the Clinical Research Ethics Committee of the First Affiliated Hospital, Zhejiang University School of Medicine. This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Clinical Research Ethics Committee of the First Affiliated Hospital, Zhejiang University School of Medicine (No. 2022971).
Participants
Inclusion criteria: admission diagnosis of hyperkalemia (serum potassium > 5.5 mmol/L); age ≥ 18 years. Exclusion criteria: age < 18 years; pregnant women; laboratory tests suggesting serum potassium < 5.5 mmol /L; incomplete clinical data or missing data on blood potassium; patients with blood potassium > 10.0 mmol/L on any occasion. A total of 1074 patients with hyperkalemia were finally included.
Research variables
We collected data based on the association of the variables with the outcomes, and then eliminated variables with a missing rate > 28%, and finally selected 52 candidate variables. These variables were recorded for the first time after admission. They included demographic variables, comorbidities, vital signs, laboratory findings, oliguria and Glasgow coma score. Demographic variables included age, gender, smoking, and alcohol consumption. Co-morbidities include hypertension, peripheral edema, diabetes mellitus, heart failure, chronic liver disease, tumors, chronic kidney disease, history of hyperkalemia, diabetic nephropathy, and acute gastrointestinal bleeding. Vital signs included heart rate, systolic blood pressure, diastolic blood pressure, mean arterial pressure, respiratory rate, body temperature, oxygen saturation (SpO2), and fraction of inspiration oxygen (FiO2). Among the laboratory results, we selected the following variables: white blood cell count, red blood cell count, hemoglobin, red blood cell pressure, platelet count, glutamic aminotransferase, serum creatinine (SCr), estimated glomerular filtration rate (eGFR), urea, uric acid, Initial and last blood potassium, sodium, chloride, total calcium, inorganic phosphorus, International standardized ratio(ISR), fibrinogen (Fib), activated partial thromboplastin time (APTT), prothrombin time (PT), thrombin time (TT), pH, partial pressure of carbon dioxide (pCO2), partial pressure of oxygen (pO2), bicarbonate concentration, base excess (BE), lactate dehydrogenase (LDH), hydroxybutyrate dehydrogenase (HBDH), and creatine kinase-MB (CKMB). Treatment was considered effective if blood K + ≤ 5.5 mmol/L checked after the last treatment. Effective and ineffective treatment groups were divided according to the last blood potassium of hospitalization. Admission adverse events included: admission to ICU, death, respiratory and cardiac arrest.
Study design
Influential factors were analyzed on the full dataset using the least absolute shrinkage and selection operator (LASSO) and multivariate logistic regression. In this retrospective cohort study, model development, validation, interpretation, and application were performed sequentially. We divided the overall random data into two parts, where 70% is used as training data and 30% as validation data. Use LASSO to filter variables in the training set. For the prediction of adverse events, the data in the training set were balanced using the SMOTE algorithm. Six ML models—XGBoost, logistic regression (LR), random forest (RF), support vector machine (SVM), k-nearest neighbor (KNN), and decision tree (DT)—were used to build predictive models. In order to improve the fairness and reliability of the comparison between models, this study used tenfold cross-validation to initially assess the performance. The data was normalized using the MinMaxScaler function in sklearn.preprocessing module before applying KNN, SVM, logistic. First, we found the optimal parameters for each of the six machine learning methods by grid search and fivefold cross-validation in the training set, and then validated them in the test set. Second, the method with the largest area under the curve (AUC) was selected for modeling. In addition, we calculated accuracy, sensitivity, specificity and F1 scores. Some algorithms were randomized, resulting in different results each time they were executed. Each algorithm was run 1200 times to reduce the possible bias introduced. Decision curves were used to assess clinical benefits. Finally, we used the SHAP method to illustrate our final model. SHAP summary plots were used to illustrate the impact of features attributed to the model. SHAP force diagrams were used to visualize the impact of key features on the final model for individual patients.
Statistical analysis
Categorical data were expressed as frequencies and percentages, and differences between groups were compared by chi-square test or Fisher's test. Continuous variables that did not conform to a normal distribution, denoted as median and interquartile range (IQR), were compared between the two groups using the Wilcoxon rank sum test. Continuous variables conformed to a normal distribution expressed as mean and standard deviation, and t-tests were used when comparing the two groups. Missing data were used the “mice” package in R to impute. Correlation between variables were analyzed using spearman. All analyses were performed using Python (v. 3.8.3) and R (v. 4.2.1, R statistical computing base). Two-tailed P values < 0.05 indicated statistical significance.
Results
Patient characteristics
A total of 1074 adult patients with a diagnosis of hyperkalemia were included in the final cohort of this study. The data set was randomly divided into 2 parts:70% (adverse events: n = 1372; therapeutic effect: n = 751) of the data were used for model training and 30% (adverse events: n = 323; therapeutic effect: n = 323) of the data were used for model validation (Supplementary Table 2; Supplementary Table 3). The group with adverse events was significantly older than the group without adverse events (P < 0.05) (Supplementary Table 1). The incidence of unsuccessful treatment was 35.553% (267/751) in the training data set and 35.604% (115/323) in the validation data set (Supplementary Table 3). Table 1 and supplementary Table 1 compare all candidate variables between the two patient groups.
Risk characterization factors for treatment effects and adverse events
The LASSO compresses variable coefficients to prevent overfitting and to address severe covariances. LASSO regression analysis was performed on the full dataset to screen variables (Supplementary Fig. 1; Supplementary Fig. 2). The results showed that 13 variables were screened for adverse events: DBP, breathing, SpO2, GCS, liver disease, oliguria, urea, uric acid, sodium, ISR, PH, BE, and initial blood potassium. The treatment effects were screened for 7 variables: peripheral edema, oliguria, eGFR, urea, sodium, BE, and initial blood potassium. The correlations between the variables were all low (Supplementary Fig. 3). To further control for the effects of confounding factors, multivariate logistic regression analysis was performed. Finally, only peripheral edema, eGFR, sodium, base excess, and Initial blood potassium were identified as influences on treatment effect (Table 2). Only DBP, breathing, SpO2, GCS, liver disease, oliguria, sodium, ISR, and initial potassium were identified as factors affecting adverse events (Supplementary Table 4).
LASSO regression analysis was performed on the training set to screen the variables. (Supplementary Fig. 4; Supplementary Fig. 5). The results showed that 15 variables were screened for adverse events: DBP, breathing, SpO2, GCS, liver disease, oliguria, Fib, uric acid, sodium, ISR, PH, BE, glutathione transaminase, FiO2, and initial blood potassium. The treatment effects were screened for 7 variables: peripheral edema, oliguria, eGFR, urea, sodium, BE, Hemoglobin, and initial blood potassium. The correlations between the variables were all low (Supplementary Fig. 6).
Model building and evaluation
Tenfold cross-validation was performed for performance evaluation. Using AUC values as the evaluation metrics and plotting box plots to initially see the distribution of predictive performance, the results showed the best performance of the XGBoost model (Supplementary Fig. 7). The LASSO-screened variables were used to build models in the training set and to predict in the test set. In Table 3 and Supplementary Table 5, we summarized the performance of the six models in terms of AUC, accuracy, sensitivity, specificity and F1 scores. In the prediction of adverse events, compared with other ML models (AUC: RF 0.779, LR 0.844, SVM 0.848, KNN 0.685, DT 0.699; accuracy: RF 0.780, LR 0.796, SVM 0.827, KNN 0.814, DT 0.770, XGBoost 0.848) (Supplementary Table 5), the XGBoost model had the best model fit performance with an AUC of 0.870 (a of Fig. 1) and a sensitivity of 0.643 in the validation cohort. The DCA measures net benefit at different threshold probabilities. The black line in Fig. 2 indicates that all patients were assumed to receive the intervention, while the dashed line indicates that all patients did not receive the intervention. The threshold probabilities range from 0.016 to 0.258, and the XGBoost model outperforms the other models in terms of net benefit (a of Fig. 2).
In predicting treatment effects, compared with other ML models (AUC: RF 0.702, LR 0.703, SVM 0.693, KNN 0.605, and DT 0.683; accuracy: RF 0.641, LR 0.666, SVM 0.613, KNN 0.619, and DT 0.694), in the validation cohort, the XGBoost model has the best model fit performance with an AUC of 0.750 and an accuracy of 0.712 (Table 3). However, the SVM model has the highest sensitivity (0.661). For threshold probabilities from 0.183 to 0.435 (or 0.488–0.685), the XGBoost model outperforms the other models in net benefit (b of Fig. 2). After considering several performance metrics together, we chose XGBoost to construct the final model. Random seeds were removed and the mean AUC and standard deviation were obtained by running each algorithm 1200 times (Supplementary Table 6; Supplementary Table 7). It could be seen that the final choice of XGBoost model was also stable.
Model explanation
The SHAP algorithm was used to derive the importance of each predictive feature on the prediction results of the XGBoost model. The feature importance plot lists the relatively significant features by descending order (Supplementary Fig. 8). SHAP feature density scatter plots showed that SpO2 had the strongest predictive value, followed by sodium, BE and initial potassium. In addition, to detect positive and negative relationships between features and target outcomes, SHAP values were applied to reveal risk factors for the occurrence of adverse events in hyperkalemia (a of Fig. 3). Figure 3 showed the distribution of all individuals on each variable, where the horizontal coordinates measured the size of the variable as it got larger to the right. The effects of features on the XGBoost model (positive or negative) are shown in Fig. 321, red represents an increased risk of death and blue represents a decreased risk of death. SHAP feature density scatter plots. It can be seen that the presence of uric acid had a positive effect and drives the prediction of an adverse event, while an increase in SPO2 had a negative effect and drives the prediction of no adverse event.
SHAP feature density scatter plots showed that initial potassium had the strongest predictive value, followed by eGFR, sodium and hemoglobin (b of Fig. 3). It can be seen that the presence of initial potassium had a positive effect and drives the prediction of an unsuccessful treatment, while an increase in eGFR had a negative effect and drives the prediction of successful treatment.
Model application
Figure 4 show the individual force maps for randomly selected patients without adverse events (a) and unsuccessful treatment (b). This patient’s SHAP value indicates the predictive variables of relevance for the individual patient and the contribution of each variable to the prediction of target event. The number on the X-axis is the SHAP value, and the values for each feature of the sample are shown below the horizontal line. Red features indicate an increased risk of target event, and blue features indicate a decreased risk of target event22. The length of the arrow is proportional to the SHAP value, the longer the arrow, the greater the prediction effect23. The contribution of some variables is too low to be shown in the figure, and only the more contributing variables are shown in Fig. 4. SHAP value for target event in patient A was − 1.99, and the actual patient survived after admission. SHAP value for target event in patient B was 0.43, and the actual patient's last potassium was greater than 5.5.
Discussion
Previously, no studies were predicting adverse events and therapeutic effect in patients with hyperkalemia admitted to the hospital, so this study is open source. The aim of this study was to predict the final potassium-lowering effect in hyperkalemic patients at an early stage, i.e., to screen out patients who are not prone to successful potassium-lowering prior to treatment, and subsequently to focus attention and treatment. Therefore, therapeutic drugs and duration of treatment were not included in this study for analysis. In this retrospective cohort study in emergency medicine, we developed and validated six ML algorithms. The XGBoost model outperformed LR, RF, SVM, KNN, and DT. The interpretation of the XGBoost model using the SHAP method ensured the clinical interpretability of the model, which allowed physicians to better understand the decision process of the model and facilitated the use of the model. In this study, we found that the developed model performs best when the DCA correlation threshold probability is in a certain range. XGBoost has been widely used to predict in-hospital mortality in patients in numerous studies. However, the rate of adverse events in the final cohort of patients with hyperkalemia was only 8.66%. The ROC curve indicated that the XGBoost model was the best, but the accuracy of the adverse event class prediction was 0.643 (sensitivity). Therefore, the XGBoost model might not fully provide decision support for clinicians. In clinical practice, it is necessary to evaluate the benefits of early prediction of adverse events and their additional costs.
The SHAP method shows the contribution of all variables to the model output not only at the macro level through the feature density scatter plots, feature importance SHAP values, but also at the micro level through the individual sample variable impact plots24. By using SHAP to interpret the XGBoost model, we identified a number of important variables associated with adverse events and therapeutic effect of hyperkalemia with hospital admission. SHAP specifies whether the effects of variables are positive or negative25. In the present study, SpO2 and initial potassium were the most important predictive feature. A more serious consequence of hyperkalemia is a decrease in myocardial resting membrane potential, which leads to a slowing of myocardial cell conduction velocity and an increase in repolarization rate3. Hyperkalemia has a significant effect on both conduction and automaticity of cardiomyocytes26, Both high potassium and low sodium affect the electrophysiological activity of cardiomyocytes, and potassium is necessary for normal cardiomyocyte function including impulse conduction and coordinated myocardial contraction9,27. Thus, disturbances in potassium levels predispose to arrhythmias, and the mechanism by which high potassium causes death in patients may be the induction of fatal arrhythmias28. Reduced tubular flow due to sodium restriction may lead to hyperkalemia29, and disturbances in both serum sodium and potassium are independently associated with poor prognosis30. The kidneys are the most important excretory site31, and when kidney function is abnormal and excretory function is impaired, it will lead to an increase in uric acid concentration. The decline in glomerular filtration capacity is a direct reflection of progressive kidney damage. Elevated levels of urea indicate an increased risk of AKI32. Under normal conditions, the kidneys excrete 90% of the daily potassium intake12,33,34, and abnormal kidney function is the most common cause of hyperkalemia18,35,36, so for patients with hyperkalemia, we should focus on the patient's kidney function37. In addition, patients with peripheral edema or oliguria were also prone to bad outcomes, and these symptoms might also suggest renal dysfunction38. Metabolic acidosis occurs in all patients prior to cardiac arrest, which can result in extracellular potassium transfer, when the base excess is too low5,33,39. It has been suggested that hyperkalemia can cause renal tubular acidosis and lead to peripheral neuropathy in patients with chronic kidney disease34. It has been noted that metabolic acidosis and AKI are independent predictors of mortality in patients hospitalized with hyperkalemia40. The GCS score is a level of consciousness score that can clearly indicate deterioration in neurological function; a lower score indicates a worse condition, and the GCS score is often associated with the risk of death. Hyperkalemia increases the risk of adverse events associated with arrhythmias, which can lead to hypotension and myocardial ischemia39. In addition, higher ISR indicates a worse prognosis for the patient, which is consistent with the actual clinical significance.
There are some limitations in this study. First, variables with missing values and high rates of missingness were removed from this study, and potentially more important characteristics were not selected for inclusion. Second, all data were from China, and there were many unmeasured confounders, such as race and treatment strategy. Third, our study lacked external validation of independent cohorts from other regions or countries, and the applicability of the developed XGBoost model in clinical practice needs further validation. Fourth, a single-center retrospective study limited our ability to identify causal relationships between variables and outcomes. Therefore, further prospective randomized controlled trials are needed to validate the validity of our model. Finally, only adults were recruited in our study, and the predictive effect of the XGBoost model on the prognosis and therapeutic effect of children with hyperkalemia is unclear. This finding needs to be interpreted with caution, and more evidence is needed to confirm it in the near future.
Conclusions
For hyperkalemia, we developed the interpretable XGBoost prediction model that performed best in predicting the risk of adverse events and therapeutic effect. In addition, applying interpretable ML can accurately identify risk factors and enhance physician confidence in the prediction model. This will help physicians to identify hyperkalemia patients with a high risk of death so that appropriate treatment measures can be taken promptly.
Data availability
De-identified data and associated code can be made available from the corresponding author upon reasonable request. Contact information for the corresponding author is included on the title page.
References
Zhang, J., He, X. & Wu, J. The impact of hyperkalemia on mortality and healthcare resource utilization among patients with chronic kidney disease: A matched cohort study in China. Front. Public Health 10, 855395. https://doi.org/10.3389/fpubh.2022.855395 (2022).
Rivera-Juárez, A. et al. Clinical characteristics and electrophysiological mechanisms underlying Brugada ECG in patients with severe hyperkalemia. J. Am. Heart Assoc. 8, e010115. https://doi.org/10.1161/jaha.118.010115 (2019).
McMahon, G. M., Mendu, M. L., Gibbons, F. K. & Christopher, K. B. Association between hyperkalemia at critical care initiation and mortality. Intensive Care Med. 38, 1834–1842. https://doi.org/10.1007/s00134-012-2636-7 (2012).
D’Alessandro, C. et al. Prevalence and correlates of hyperkalemia in a renal nutrition clinic. Intern. Emerg. Med. 16, 125–132. https://doi.org/10.1007/s11739-020-02353-9 (2021).
Campese, V. M. & Adenuga, G. Electrophysiological and clinical consequences of hyperkalemia. Kidney Int. Suppl. 2011(6), 16–19. https://doi.org/10.1016/j.kisu.2016.01.003 (2016).
Hundemer, G. L. et al. Ambulatory treatments for RAAS inhibitor-related hyperkalemia and the 1-year risk of recurrence. Clin. J. Am. Soc. Nephrol. 16, 365–373. https://doi.org/10.2215/cjn.12990820 (2021).
Regolisti, G. et al. Electrocardiographic T wave alterations and prediction of hyperkalemia in patients with acute kidney injury. Intern. Emerg. Med. 15, 463–472. https://doi.org/10.1007/s11739-019-02217-x (2020).
An, J. N. et al. Severe hyperkalemia requiring hospitalization: Predictors of mortality. Crit. Care 16, R225. https://doi.org/10.1186/cc11872 (2012).
Krogager, M. L. et al. Impact of plasma potassium normalization on short-term mortality in patients with hypertension and hyperkalemia. J. Am. Heart Assoc. 9, e017087. https://doi.org/10.1161/jaha.120.017087 (2020).
Esposito, P. et al. New treatment options for hyperkalemia in patients with chronic kidney disease. J. Clin. Med. https://doi.org/10.3390/jcm9082337 (2020).
Ben Salem, C., Badreddine, A., Fathallah, N., Slim, R. & Hmouda, H. Drug-induced hyperkalemia. Drug Saf. 37, 677–692. https://doi.org/10.1007/s40264-014-0196-1 (2014).
Seliger, S. L. Hyperkalemia in patients with chronic renal failure. Nephrol. Dial. Transplant. 34, iii12–iii18. https://doi.org/10.1093/ndt/gfz231 (2019).
Bushinsky, D. A. et al. Patiromer induces rapid and sustained potassium lowering in patients with chronic kidney disease and hyperkalemia. Kidney Int. 88, 1427–1433. https://doi.org/10.1038/ki.2015.270 (2015).
Thongprayoon, C. et al. Distinct phenotypes of hospitalized patients with hyperkalemia by machine learning consensus clustering and associated mortality risks. QJM 115, 442–449. https://doi.org/10.1093/qjmed/hcab194 (2022).
Kovesdy, C. P. Epidemiology of hyperkalemia: An update. Kidney Int. Suppl. 2011(6), 3–6. https://doi.org/10.1016/j.kisu.2016.01.002 (2016).
Luo, J., Brunelli, S. M., Jensen, D. E. & Yang, A. Association between serum potassium and outcomes in patients with reduced kidney function. Clin. J. Am. Soc. Nephrol. 11, 90–100. https://doi.org/10.2215/CJN.01730215 (2016).
Kashihara, N., Kohsaka, S., Kanda, E., Okami, S. & Yajima, T. Hyperkalemia in real-world patients under continuous medical care in Japan. Kidney Int. Rep. 4, 1248–1260. https://doi.org/10.1016/j.ekir.2019.05.018 (2019).
Chen, Y. et al. Serum potassium, mortality, and kidney outcomes in the atherosclerosis risk in communities study. Mayo Clin. Proc. 91, 1403–1412. https://doi.org/10.1016/j.mayocp.2016.05.018 (2016).
Hughes-Austin, J. M. et al. The relation of serum potassium concentration with cardiovascular events and mortality in community-living individuals. Clin. J. Am. Soc. Nephrol. 12, 245–252. https://doi.org/10.2215/cjn.06290616 (2017).
Kovesdy, C. P. et al. Serum potassium and adverse outcomes across the range of kidney function: A CKD Prognosis Consortium meta-analysis. Eur. Heart J. 39, 1535–1542. https://doi.org/10.1093/eurheartj/ehy100 (2018).
Kuno, T. et al. Prediction of in-hospital mortality with machine learning for COVID-19 patients treated with steroid and remdesivir. J. Med. Virol. 94, 958–964. https://doi.org/10.1002/jmv.27393 (2022).
Dong, Z. et al. Prediction of 3-year risk of diabetic kidney disease using machine learning based on electronic medical records. J. Transl. Med. 20, 143. https://doi.org/10.1186/s12967-022-03339-1 (2022).
Fahmy, A. S. et al. An explainable machine learning approach reveals prognostic significance of right ventricular dysfunction in nonischemic cardiomyopathy. JACC Cardiovasc. Imaging 15, 766–779. https://doi.org/10.1016/j.jcmg.2021.11.029 (2022).
Tseng, P. Y. et al. Prediction of the development of acute kidney injury following cardiac surgery by machine learning. Crit. Care 24, 478. https://doi.org/10.1186/s13054-020-03179-9 (2020).
Zou, Y. et al. Extreme gradient boosting model to assess risk of central cervical lymph node metastasis in patients with papillary thyroid carcinoma: Individual prediction using SHapley Additive exPlanations. Comput. Methods Programs Biomed. 225, 107038. https://doi.org/10.1016/j.cmpb.2022.107038 (2022).
Janjua, H. S., Mahan, J. D., Patel, H. P., Mentser, M. & Schwaderer, A. L. Continuous infusion of a standard combination solution in the management of hyperkalemia. Nephrol. Dial. Transplant. 26, 2503–2508. https://doi.org/10.1093/ndt/gfq734 (2011).
Brueske, B. et al. Hyperkalemia is associated with increased mortality among unselected cardiac intensive care unit patients. J. Am. Heart Assoc. 8, e011814. https://doi.org/10.1161/jaha.118.011814 (2019).
Pluijmen, M. J. & Hersbach, F. M. Images in cardiovascular medicine. Sine-wave pattern arrhythmia and sudden paralysis that result from severe hyperkalemia. Circulation 116, e2–e4. https://doi.org/10.1161/circulationaha.106.687202 (2007).
Kovesdy, C. P. Management of hyperkalemia: An update for the internist. Am. J. Med. 128, 1281–1287. https://doi.org/10.1016/j.amjmed.2015.05.040 (2015).
Pfortmüller, C. A., Leichtle, A. B., Fiedler, G. M., Exadaktylos, A. K. & Lindner, G. Hyperkalemia in the emergency department: Etiology, symptoms and outcome of a life threatening electrolyte disorder. Eur. J. Intern. Med. 24, e59-60. https://doi.org/10.1016/j.ejim.2013.02.010 (2013).
Weir, M. R. Current and future treatment options for managing hyperkalemia. Kidney Int. Suppl. 2011(6), 29–34. https://doi.org/10.1016/j.kisu.2016.01.005 (2016).
Shao, M. et al. Acute kidney injury is associated with severe infection and fatality in patients with COVID-19: A systematic review and meta-analysis of 40 studies and 24,527 patients. Pharmacol. Res. 161, 105107. https://doi.org/10.1016/j.phrs.2020.105107 (2020).
Panuccio, V. et al. Epidemiology of hyperkalemia in CKD patients under nephrological care: A longitudinal study. Intern. Emerg. Med. 16, 1803–1811. https://doi.org/10.1007/s11739-021-02653-8 (2021).
Hunter, R. W. & Bailey, M. A. Hyperkalemia: Pathophysiology, risk factors and consequences. Nephrol. Dial. Transplant. 34, iii2–iii11. https://doi.org/10.1093/ndt/gfz206 (2019).
Montford, J. R. & Linas, S. How dangerous is hyperkalemia?. J. Am. Soc. Nephrol. 28, 3155–3165. https://doi.org/10.1681/asn.2016121344 (2017).
Karaboyas, A. et al. Hyperkalemia excursions are associated with an increased risk of mortality and hospitalizations in hemodialysis patients. Clin. Kidney J. 14, 1760–1769. https://doi.org/10.1093/ckj/sfaa208 (2021).
Kovesdy, C. P. Updates in hyperkalemia: Outcomes and therapeutic strategies. Rev. Endocr. Metab. Disord. 18, 41–47. https://doi.org/10.1007/s11154-016-9384-x (2017).
Lu, X., Yang, Y. M. & Lu, Y. Q. Immunosenescence: A critical factor associated with organ injury after sepsis. Front. Immunol. 13, 917293. https://doi.org/10.3389/fimmu.2022.917293 (2022).
Hougen, I. et al. Hyperkalemia and its association with mortality, cardiovascular events, hospitalizations, and intensive care unit admissions in a population-based retrospective cohort. Kidney Int. Rep. 6, 1309–1316. https://doi.org/10.1016/j.ekir.2021.02.038 (2021).
Rossignol, P. et al. Emergency management of severe hyperkalemia: Guideline for best practice and opportunities for the future. Pharmacol. Res. 113, 585–591. https://doi.org/10.1016/j.phrs.2016.09.039 (2016).
Funding
This study was supported by the Foundation of Key Research Project of Zhejiang Province for Traditional Chinese Medicine (No. 2019ZZ014).
Author information
Authors and Affiliations
Contributions
Y.Q.L. and W.H. conceived the idea. W.H., C.Y.S. and J.Y.Z. collected data. W.H. analyzed the data. W.H. and J.Y.Z. drafted the manuscript. All authors reviewed the manuscript.
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Additional information
Publisher's note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary Information
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Huang, W., Zhu, JY., Song, CY. et al. Machine learning models for early prediction of potassium lowering effectiveness and adverse events in patients with hyperkalemia. Sci Rep 14, 737 (2024). https://doi.org/10.1038/s41598-024-51468-y
Received:
Accepted:
Published:
DOI: https://doi.org/10.1038/s41598-024-51468-y
- Springer Nature Limited